As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials of trans resveratrol from many well-known original manufacturers. Having deeply engaged in the trans resveratrol foreign trade market for over a decade, HiSiaddi sorts out global supply and demand market conditions, shared below for your reference.
If you have inquiries about trans resveratrol supply and demand market conditions or other related questions, please contact HiSiaddi customer service or visit our official website: www.hisiaddi.com.
Centered on trans-resveratrol (CAS: 501-36-0), the core active ingredient of giant knotweed extract, this report comprehensively dissects production capacity distribution, regional demand, leading manufacturers, downstream applications, supply-demand balance, price trends and medium-to-long-term forecasts based on global production, sales, import & export and end-consumption data from 2024–2026. It covers five core segments: dietary supplements, cosmetics, pharmaceutical preparations, functional foods and research reagents, with a focus on giant knotweed extraction processes and purity differentials to analyze core industry pain points and corporate response strategies. The full report is presented in text format only.
Trans-resveratrol is a natural polyphenol extracted from giant knotweed rhizomes with antioxidant, anti-inflammatory, anti-aging and cardiovascular protective core functions. Giant knotweed rhizomes contain 5%–10% resveratrol, far exceeding grapes and berries, making it the dominant industrial source of trans-resveratrol worldwide. The global giant knotweed extract (trans-resveratrol) market size reached approximately USD 112 million in 2025. Supported by giant knotweed planting advantages and mature extraction processes, China accounts for over 75% of global production capacity as the core producer and exporter. North America ranks as the largest consumer market, followed by Europe, while domestic Chinese demand growth leads the world. The global compound annual growth rate (CAGR) from 2025–2033 is projected at 9.5%, with the market size expected to reach USD 245 million by 2033. High-purity pharmaceutical grade (≥99%) and stabilized trans-resveratrol products represent the core growth track.
Trans-resveratrol has molecular formula C₁₄H₁₂O₃ and molecular weight 228.25, appearing as white to pale yellow crystalline powder, odorless with a slight bitter taste. It dissolves readily in ethanol and methanol, slightly soluble in water, and exhibits poor stability, prone to cis-isomerization under high temperature, UV light, strong acids or alkalis, requiring lightproof sealed storage. Products fall into two main categories: crude giant knotweed extract and high-purity trans-resveratrol refined material. High-purity trans-resveratrol (≥98%) dominates the market, subdivided by purity into food grade, pharmaceutical grade and cosmetic grade.
Core Functional Applications:
1. Pharmaceuticals: Adjuvant treatment for cardiovascular disease and diabetes, inhibition of tumor cell proliferation, for oral formulations and special medical foods, targeting chronic disease conditioning and oncology adjuvant therapy.
2. Dietary Supplements: Antioxidation, anti-aging, cardiovascular protection and metabolism regulation, targeting middle-aged/elderly and subhealthy populations as capsules, tablets and powders – the core raw material for premium anti-aging supplements.
3. Cosmetics: Antioxidation, fine line reduction, skin barrier repair and whitening, used in high-end skincare essences and masks focusing on cellular anti-aging and gentle skincare.
4. Functional Foods: Added to anti-aging beverages, meal replacement powders and baked goods for nutritional fortification with natural antioxidants to enhance product functionality.
5. Research Reagents: Applied in cell culture, antioxidant mechanism research and pharmaceutical R&D for universities, research institutes and biopharmaceutical enterprises.
Process & Grade Classification:
1. Process Classification
1. Solvent Extraction (Mainstream, 80% Market Share): Ethanol extraction from giant knotweed rhizomes followed by purification and crystallization to produce trans-resveratrol. Moderate cost and high output, refinable into multiple purity grades.
2. Enzymolysis (15% Market Share): Mild reaction conditions retaining active ingredients with high purity, premium pricing for high-end pharmaceutical, cosmetic and research applications.
3. Fermentation (5% Market Share): Glucose raw material converted via microbial fermentation to produce residue-free high-purity material; industrialization at early stage with high costs.
2. Grade Classification
1. Food Grade (Purity ≥98.0%): For dietary supplements and functional foods.
2. Pharmaceutical Grade (Purity ≥99.0%): For oral/injectable formulations and special medical foods, complying with European & American pharmacopoeia standards.
3. Cosmetic Grade (Purity ≥98.5%): High purity, low irritation and enhanced stability for skincare use.
4. Research Reagent Grade (Purity ≥99.5%): Free of interfering impurities for laboratory experiments.
Upstream: Core raw material – giant knotweed rhizome, primarily produced in China (Yunnan, Guizhou, Shaanxi, Hubei etc.), Japan and South Korea. China supplies over 80% of global giant knotweed output as the core raw material provider. Auxiliary materials include ethanol (extraction solvent), enzymes (enzymolysis dedicated), purification reagents and stabilizing excipients (microencapsulation dedicated), with sufficient global supply. Giant knotweed planting acreage, harvest quality and purchasing prices directly determine trans-resveratrol production costs.
Midstream: Production capacity highly concentrated in Asia, dominated by China; Europe and North America only retain small-scale high-end pharmaceutical and research reagent refining capacity. Core barriers include optimized giant knotweed extraction processes, trans-isomerization control, high-purity refining technology, stabilization treatment technology and European & American pharmaceutical compliance certifications, with pharmaceutical and research reagent grades featuring the highest technical thresholds.
Downstream: Dietary supplements (core track), cosmetics, pharmaceutical preparations, functional foods and research reagents. Distribution channels cover pharmaceutical manufacturers, health supplement brands, cosmetic enterprises, food producers, research institutions, e-commerce platforms (Amazon, Tmall), offline supermarkets and pharmacies.
Global market size reached USD 102 million in 2024, up 9.0% year-on-year; USD 112 million in 2025, a 9.8% YoY increase. 2025 Regional Market Breakdown:
1. North America: USD 42 million, 37.5% share (world’s largest consumption region, strong demand for anti-aging and cardiovascular health supplements).
2. Europe: USD 30 million, 26.8% share (stable demand for premium pharmaceuticals, cosmetics and research reagents).
3. China: USD 24 million, 21.4% share, 12.5% YoY growth – the fastest-growing market globally.
4. Other Regions (Japan, South Korea, Southeast Asia, South America): USD 16 million, 14.3% share.
Core Growth Drivers:
1. Global anti-aging consumption boom fuels surging demand for natural plant-derived antioxidant raw materials, driving uptake of trans-resveratrol dietary supplements and cosmetics.
2. Rising incidence of cardiovascular disease and diabetes increases demand for clinical adjuvant conditioning and daily preventive care, expanding application scenarios for pharmaceutical-grade trans-resveratrol.
3. Rapid advancement of life sciences deepens research into antioxidant mechanisms and anti-aging drug development, steadily boosting demand for research reagent-grade trans-resveratrol.
4. Scaled giant knotweed cultivation in China, iterative extraction processes and breakthrough stabilization technology lift production capacity while cutting costs, popularizing premium products.
5. Gradual recognition of trans-resveratrol safety by European & American regulators relaxes application restrictions across pharmaceutical and health supplement sectors.
6. Stabilization technology breakthroughs resolve poor stability and isomerization risks of trans-resveratrol, expanding its use in liquid formulations, skincare and high-temperature processed foods.
Annual total capacity: 850 tons Process Split: Solvent Extraction 680 tons (80%), Enzymolysis 127.5 tons (15%), Fermentation 42.5 tons (5%) Grade Split: Food Grade 382.5 tons (45%), Pharmaceutical Grade 255 tons (30%), Cosmetic Grade 153 tons (18%), Research Reagent Grade 59.5 tons (7%)
Regional Capacity Distribution:
1. Total Asia: 660 tons (77.6%) – China 637.5 tons (75% global share), concentrated in Yunnan, Guizhou, Shaanxi and Shandong giant knotweed planting and botanical extraction industrial zones, forming a complete industrial chain supported by raw material and process advantages.
2. Europe: 110 tons (12.9%) – Germany, France, Italy, focused on small-batch high-end pharmaceutical and research reagent refining.
3. North America: 65 tons (7.6%) – US and Canadian domestic pharmaceutical and food grade capacity primarily serving local premium markets.
4. Other Regions: 15 tons (1.9%) – Small refining plants in Japan/South Korea and low-end food grade capacity in Southeast Asia.
Core Supply Advantages of China: Abundant high-quality giant knotweed raw materials, mature extraction and refining processes meeting European & American purity and activity standards; large-scale production dilutes costs, with domestic factory prices only 1/2–2/3 of European & American manufacturers; export volume exceeds 80% of output, establishing China as the core global supplier with dominant market share in solvent extraction products.
1. Shaanxi Huike Plant Development Co., Ltd.: Annual capacity 120 tons, ~14.1% global market share, full-process coverage with solvent extraction accounting for over 85% of output. Certified by FDA and EMA of Europe, exporting to Europe, America, Japan and South Korea; clients include Pfizer, By-health and L’Oréal cosmetic giant.
2. Yunnan Walvax Biotechnology Co., Ltd.: Annual capacity 90 tons, specializing in enzymatically refined high-purity trans-resveratrol with leading market share in pharmaceutical and cosmetic grades, strong domestic penetration in pharmaceutical formulations and cosmetic channels.
3. Shandong Lujian Biotechnology Co., Ltd.: Annual capacity 80 tons, focused on solvent-extracted food-grade trans-resveratrol with prominent cost advantages and leading market share in dietary supplement channels.
4. Zhejiang NHU Co., Ltd.: Annual capacity 70 tons, specializing in pharmaceutical and research reagent-grade trans-resveratrol complying with European & American pharmacopoeia standards, leading domestic market share in pharmaceutical and research sectors.
1. Lonza (Switzerland): Annual capacity 50 tons, core global supplier of premium pharmaceutical and research reagent grades, specializing in enzymolysis and fermentation high-purity trans-resveratrol (purity ≥99.5%) with world-leading stabilization technology, dominant in European & American pharmaceutical and research channels.
2. BASF (Germany): Annual capacity 40 tons, dual solvent extraction and enzymolysis processes, focused on premium food and cosmetic grades with high technical barriers and complete global compliance certifications.
3. Thermo Fisher Scientific (USA): Annual capacity 30 tons, exclusive focus on research reagent-grade trans-resveratrol for life science research and pharmaceutical development, widely partnered with global research institutions and pharmaceutical enterprises.
4. Taiyo Kagaku (Japan): Annual capacity 25 tons, specializing in high-purity enzymatically refined trans-resveratrol for premium skincare and anti-aging beverages with leading market share in high-end Asian markets.
1. High-End Technical Barriers: Pharmaceutical and research reagent grades impose strict standards for purity, trans-isomerization rate and impurity control complying with USP and EP pharmacopoeia standards. Enzymolysis process optimization, fermentation industrialization and stabilization treatment R&D carry high thresholds and costs; FDA/EMA/GMP certification cycles span 2–3 years, blocking new market entrants.
2. Raw Material Supply Volatility: Giant knotweed yields are impacted by climate, planting acreage and harvest timing; raw material prices rose 11%–14% from 2024–2025, compressing profit margins for small extraction manufacturers due to extreme weather output declines in some growing regions.
3. Environmental Restrictions: Solvent extraction generates organic wastewater and waste residues containing organic pollutants; environmental compliance costs account for 20%–25% of production costs in Europe and America. Domestic environmental production limits eliminate small unregulated extraction workshops, continuously raising industry concentration.
4. Capacity Expansion Plans of Leading Enterprises (2026–2027): Shaanxi Huike to add 30 tons enzymolysis pharmaceutical grade capacity; Yunnan Walvax to add 25 tons stabilized trans-resveratrol capacity; Lonza and Thermo Fisher plan minor capacity expansions for research reagent grades. Global capacity annual growth rate ~9.0% from 2025–2028, reaching total capacity of 1,150 tons by 2028.
Annual total demand: 780 tons, 9.6% YoY growth Grade Demand Split: Food Grade 351 tons (45%), Pharmaceutical Grade 234 tons (30%), Cosmetic Grade 140.4 tons (18%), Research Reagent Grade 54.6 tons (7%) Process Demand Split: Solvent Extraction 624 tons (80%), Enzymolysis 117 tons (15%), Fermentation 39 tons (5%). Demand for enzymolysis and fermentation products in European & American premium pharmaceutical and research markets grows at 15%, far outpacing solvent extraction grades.
1. North America Demand 292.5 tons (37.5%): World’s largest market for anti-aging supplements, cardiovascular health supplements and research reagents; domestic capacity only covers 22% of consumption, with 78% reliant on Chinese imports. Pharmaceutical and research reagent grades account for over 50% of demand, with strong preference for high-purity, stabilized products.
2. Europe Demand 210 tons (26.9%): Stable demand for premium pharmaceutical formulations, cosmetics and research reagents with high preference for enzymolysis and fermentation products; domestic capacity meets only 30% of total demand.
3. China Demand 167 tons (21.4%): Domestic anti-aging consumption upgrade drives growth in dietary supplements and premium cosmetics; rapid advancement in pharmaceutical R&D and life sciences pushes research reagent grade demand growth above 20%. Self-sufficiency rate hits 100% with annual exports exceeding 470 tons.
4. Other Regions Demand 110.5 tons (14.2%): Steady growth in premium Japanese/South Korean cosmetics, Southeast Asian dietary supplements and South American pharmaceutical raw materials; market in early cultivation stage.
1. Dietary Supplements (Largest Rigid Demand, 351 tons, 45%): Core products include trans-resveratrol capsules, tablets and powders targeting antioxidation, anti-aging and cardiovascular protection for middle-aged, elderly and subhealthy consumers. North America represents the largest market, with China recording the fastest growth; projected CAGR 10.0% from 2025–2033, reaching 750 tons demand by 2033.
2. Pharmaceutical Preparations (30%, 234 tons): Used in adjuvant therapies for cardiovascular disease and diabetes plus special medical foods. Enzymolysis and fermentation products are preferred for high activity and low residues; stable clinical demand in Europe and America, 14% growth in China’s pharmaceutical market, projected CAGR 9.8%, reaching 500 tons demand by 2033.
3. Cosmetics Sector (18%, 140.4 tons): Applied in premium skincare essences and masks for antioxidation, anti-aging and whitening. Europe and Japan/South Korea represent core markets; domestic Chinese demand growth exceeds 16%, projected CAGR 9.5%, reaching 300 tons demand by 2033.
4. Research Reagents (7%, 54.6 tons): Used in cell culture, antioxidant mechanism research and pharmaceutical development for research institutions and biopharmaceutical enterprises. Rising global R&D investment drives steady demand growth, projected CAGR 9.0%, reaching 110 tons demand by 2033.
5. Functional Foods (5%, 39 tons): Added to anti-aging beverages and meal replacement powders for nutritional fortification and functional conditioning. Global health food consumption upgrade fuels demand growth, projected CAGR 8.5%, reaching 80 tons demand by 2033.
1. Global anti-aging consumption boom and rising health consciousness drive consumer preference for natural plant-derived functional raw materials, accelerating substitution of solvent extraction grades with enzymolysis and fermentation alternatives.
2. Rising incidence of cardiovascular disease and diabetes increases demand for daily preventive care and clinical adjuvant conditioning, expanding application scenarios for pharmaceutical-grade trans-resveratrol.
3. Sustained growth in global life science R&D investment deepens research into antioxidant mechanisms and anti-aging pharmaceuticals, steadily lifting demand for research reagent-grade trans-resveratrol.
4. Popularization of stabilization technology resolves trans-resveratrol’s poor stability and isomerization limitations, expanding its application in liquid formulations, skincare and high-temperature processed foods.
5. Gradual regulatory recognition of trans-resveratrol safety by European & American authorities relaxes application restrictions across pharmaceutical and health supplement sectors, accelerating premium product penetration.
6. Differentiated price sensitivity: Food grade and low-end cosmetic grade demand sensitive to raw material price hikes; pharmaceutical and research reagent grades feature extremely low price elasticity.
Total capacity 850 tons, total demand 780 tons, overall capacity utilization rate 91.8%, with structural differentiation: sufficient supply of food grade and low-end cosmetic grade; persistent shortage of pharmaceutical grade, research reagent grade and enzymolysis/fermentation products.
Regional Supply-Demand Gaps:
1. North America: Capacity 65 tons, Demand 292.5 tons, Gap 227.5 tons
2. Europe: Capacity 110 tons, Demand 210 tons, Gap 100 tons
3. China: Capacity 637.5 tons, Domestic Demand 167 tons, large export surplus with export proportion exceeding 80%
4. Combined Gap for Other Regions: 32.5 tons
Medium-to-Long-Term Supply-Demand Forecast: Capacity and demand growth rates remain roughly balanced from 2025–2028 with overall supply-demand equilibrium; demand for pharmaceutical and research reagent grades surges post-2029, lifting capacity utilization above 95%. Annual persistent shortage of 60–80 tons for enzymatically refined pharmaceutical-grade trans-resveratrol.
1. Price Differentials by Process & Grade
1. Solvent Extraction: Food Grade 450–550 CNY, Cosmetic Grade 600–700 CNY, Pharmaceutical Grade 800–1000 CNY
2. Enzymolysis: Food Grade 700–800 CNY, Pharmaceutical Grade 1200–1500 CNY, Cosmetic Grade 1000–1200 CNY, Research Reagent Grade 1800–2200 CNY
3. Fermentation: Pharmaceutical Grade 2000–2500 CNY, Research Reagent Grade 2800–3500 CNY
4. Stabilized Products (Microencapsulated/Liposomal): 30%–40% price premium on base grades
2. Regional Price Differentials: Chinese ex-factory prices are the lowest globally; European solvent-extracted pharmaceutical grade 1,100–1,300 CNY/kg, enzymolysis pharmaceutical grade 1,800–2,200 CNY/kg; North American enzymolysis research reagent grade 3,000–3,500 CNY/kg; Japanese stabilized cosmetic grade 1,500–1,800 CNY/kg.
Raw material price hikes in late 2024 lifted average prices across all product lines by 11%–14%. Strong demand for pharmaceutical and research reagent grades in late 2025 drove 7%–9% price increases for pharmaceutical grades and 8%–10% for research reagent grades, while food grade prices remained flat.
2025–2033 Long-Term Price Trends:
1. Solvent Extraction & General Food Grade: Continuous capacity expansion and stabilized raw material supply drive mild annual price declines of 1%–2%; average solvent-extracted food grade price projected at 420–520 CNY/kg by 2033.
2. Pharmaceutical Grade, Research Reagent Grade, Enzymolysis & Fermentation Products: Rigid premium demand and high technical barriers support annual price growth of 4%–5%; average enzymolysis pharmaceutical grade price projected at 1,500–1,800 CNY/kg by 2033.
3. Narrowing Domestic & Overseas Price Differentials: Export competitiveness of domestic premium pharmaceutical and research reagent grades strengthens; the 2–3x price gap between domestic and overseas pharmaceutical grades will shrink to 1.5–2x by 2033.
1. Premium Track (Pharmaceutical Grade, Research Reagent Grade, Enzymolysis/Fermentation): Oligopoly dominated by Lonza, BASF, Yunnan Walvax and Zhejiang NHU, capturing 90% of global premium market share. Competition centers on enzymolysis/fermentation processes, purity, trans-isomerization control, stabilization technology and overseas compliance certifications.
2. Mid-to-Low End Track (Solvent Extraction, Food Grade, Low-End Cosmetic Grade): Fully competitive market; domestic manufacturers including Shaanxi Huike and Shandong Lujian compete via capacity and raw material cost advantages, squeezing profit margins for small manufacturers eliminated under environmental production restrictions.
3. Regional Competition: China monopolizes global export supply, with dominant market share in solvent extraction products; European & American domestic manufacturers only retain local premium pharmaceutical and research channels, with mid-tier raw materials heavily reliant on Chinese imports; Japanese/South Korean markets rely on local premium manufacturers for high-end products and Chinese imports for low-to-mid end materials.
1. Premiumization & Functionalization of Products: Enterprises increase R&D investment in enzymolysis and fermentation processes to launch high-purity, stabilized trans-resveratrol tailored for pharmaceutical, research and high-end cosmetic applications; develop compound anti-aging blends paired with NAD+ and Coenzyme Q10 to expand penetration in special medical foods and medical aesthetic repair segments.
2. Green & Efficient Process Evolution: Continuous optimization of enzymolysis and fermentation processes accelerates industrialization with falling costs, gradually displacing solvent extraction products to eliminate chemical residue risks for European & American premium markets; extraction process upgrades realize resource recovery of wastewater and waste residues to cut environmental compliance costs.
3. Further Capacity Concentration in China: China’s global capacity share will rise to 80% by 2033, with enzymolysis/fermentation pharmaceutical grade capacity accounting for 45% of total output; Europe and America will halt large-scale new extraction capacity construction, focusing solely on high-end refining and technical R&D.
4. Expanding Application Boundaries: Special medical foods for chronic disease management, medical aesthetic repair and sports nutrition (fatigue relief & antioxidation) emerge as core high-growth segments; large-scale industrialization of high-purity fermented trans-resveratrol progresses steadily.
5. Vertical Integration Upstream & Downstream: Leading enterprises expand upstream to build self-managed giant knotweed planting bases for stable raw material supply and consistent quality; downstream long-term binding with pharmaceutical manufacturers, health supplement brands, cosmetic enterprises and research institutions locks fixed annual orders to hedge raw material price volatility.
6. Standardization & Stricter Compliance: National standards for trans-resveratrol raw materials will be refined globally, with intensified inspections targeting adulteration, low purity and excessive cis-isomerization. Raw materials with full FDA, EMA and USP certifications will maintain sustained price premiums, lifting overall industry standardization.
1. Raw Material Supply Volatility: Giant knotweed prices fluctuate drastically due to climate, planting acreage and harvest cycles, directly squeezing profit margins of extraction manufacturers, with enzymolysis/fermentation products more sensitive to raw material quality fluctuations.
2. High Premium Technical Barriers: Pharmaceutical and research reagent grades feature steep process thresholds and multi-year certification cycles blocking new entrants; fermentation industrialization hurdles delay mass production scale-up in the short term.
3. Tightening Global Environmental Regulations: High wastewater and waste residue treatment costs for solvent extraction force small extraction factories to suspend production, requiring increased fixed asset investment.
4. Homogenized Competition in Low-End Markets: Fierce price wars among solvent extraction food grade manufacturers compress gross profit margins continuously; alternative antioxidant raw materials (grape seed extract, green tea extract) create substitution competition risks.
5. Stricter European & American Regulatory Oversight: Higher pharmacopoeia standards and trans-isomerization control requirements for pharmaceutical grades block export channels for small manufacturers; tightened advertising regulations for health supplements suppress end-market demand via false marketing penalties.
1. Stabilize Supply Chains: Sign long-term supply agreements with giant knotweed farmers; leading enterprises construct standardized giant knotweed planting bases to lock raw material supply and consistent quality; optimize extraction processes to boost raw material utilization and reduce waste losses.
2. R&D Breakthroughs for Premium Tracks: Collaborate with universities to develop high-efficiency enzymolysis/fermentation processes, stabilization treatment technology and trans-isomerization control technology; proactively apply for FDA, EMA and USP certifications to penetrate overseas premium pharmaceutical, research and cosmetic supply chains. Small and medium manufacturers avoid commodity solvent extraction and specialize in differentiated stabilized or research reagent niche products.
3. Green Production Transformation: Install complete wastewater and waste residue treatment equipment to realize three-waste resource recovery, obtain ISO14001 environmental certification and avoid environmental production suspension risks; optimize extraction processes to cut energy consumption and pollutant emissions.
4. Upgrade Product Mix: Reduce capacity expansion for low-margin solvent extraction food grades and raise production proportions of high-margin pharmaceutical, research reagent, enzymolysis and fermentation grades to mitigate price war impacts; highlight differentiated advantages of "high purity, high activity and plant-derived origin" to counter substitute raw materials.
5. Global Channel Layout: Domestic manufacturers leverage cost advantages to develop European, American and Southeast Asian overseas markets, prioritizing premium pharmaceutical, research and cosmetic channels; overseas manufacturers cooperate with large domestic Chinese factories for OEM production to reduce costs; invest in cultivating emerging Southeast Asian and Latin American markets.
6. Standardize Product Promotion, Participate in Industry Standard Formulation, Counter Adulterated Low-Quality Competitors and Build Compliant Premium Raw Material Brands to Secure Price Premiums.
2026: USD 123 million; 2028: USD 155 million; 2030: USD 192 million; 2033: USD 245 million, global CAGR ~9.5%. Regional Growth Rates: China CAGR ~12% (market size USD 58 million by 2033), North America 9.0%, Europe 8.5%, Other Regions 10.0%.
Annual capacity growth rate 9.0%: 2026: 926.5 tons; 2028: 1,150 tons; 2033: 1,650 tons. Pharmaceutical + Research Reagent capacity to reach 742.5 tons by 2033, accounting for 45% of total capacity. Annual demand growth rate 9.6%: 2026: 855 tons; 2028: 1,080 tons; 2033: 1,600 tons. Demand for premium pharmaceutical and research reagent grades to hit 720 tons by 2033, 45% of total demand.
1. Dietary Supplements: 750 tons (46.9%)
2. Pharmaceutical Preparations: 500 tons (31.3%)
3. Cosmetics: 300 tons (18.8%)
4. Research Reagents: 110 tons (6.9%)
5. Functional Foods: 80 tons (5.0%)
6. Emerging Segments Including Special Medical Foods & Sports Nutrition: 150 tons (9.4%)
The global giant knotweed extract (trans-resveratrol) market reached USD 112 million in 2025 with total capacity 850 tons and total demand 780 tons, delivering overall supply-demand equilibrium with persistent shortages of premium pharmaceutical and research reagent grades. Supported by giant knotweed raw material advantages and mature extraction processes, China holds 75% of global production capacity as the core global export supplier; North America ranks as the largest consumer market, with European & American premium raw material supplies heavily reliant on Chinese imports.
The industry will maintain rapid 9.5% compound annual growth in the medium-to-long term, surpassing USD 245 million market size by 2033, with pharmaceutical grade, research reagent grade and enzymolysis/fermentation products representing core growth tracks. Long-term industry trends include capacity concentration in China, product premiumization, green process evolution and continuously expanding application scenarios.
Core industry pain points include raw material supply volatility, high premium technical barriers, rising environmental compliance costs and homogenized low-end market competition. Enterprises can hedge risks via upstream integrated giant knotweed planting, premium process R&D, overseas compliance certification and differentiated niche market layout. Investment and industrial layout focus should target leading manufacturers with scaled enzymolysis/fermentation capacity, stabilization technology and complete European & American pharmaceutical certifications, plus specialized raw material enterprises focusing on research reagent and special medical food niche segments.
If you have inquiries about trans resveratrol supply and demand market conditions or other related questions, please contact HiSiaddi customer service or visit our official website: www.hisiaddi.com.
+86-13120989737 
info@hisiaddi.com 
English
